+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
All Ages
All Genders
ID06787560

Study of CD7 CAR-T Cell Therapy Followed by Allogeneic Stem Cell Transplant for Non-Cancerous Blood and Immune Diseases

Led by Zhejiang University · Updated on 2025-01-22

20

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and effectiveness of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for people with non-malignant blood and immune system diseases. These conditions include hereditary bone marrow failure, congenital immune deficiencies, hemoglobinopathy, and other related diseases. This early phase 1 clinical trial aims to evaluate this treatment approach to improve care for these patients. Participants will undergo leukapheresis to collect cells from patients or donors. Before receiving the CD7 CAR-T cell infusion, patients will have lymphodepletion chemotherapy with drugs called CTX, Flu, and VP-16. The CAR-T cells are given intravenously about 48 hours after this preconditioning. The treatment combines the CAR-T cells infusion followed by allogeneic hematopoietic stem cell transplantation allo-HSCT. During the study, participants will be monitored for safety and effectiveness up to two years after treatment. Assessments include tracking adverse events, transplant-related mortality within 100 days, engraftment of stem cells, and survival outcomes. Various tests such as echocardiography, blood tests, and ultrasonography will be done, along with clinical evaluations and informed consent processes. The study plans to enroll 12 to 20 participants and includes ongoing follow-up to understand treatment impact.

CONDITIONS

Brief Title

CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases

Research Team

H

He Huang, MD

Y

Yongxian Hu, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here